Skip to main content
Erschienen in: Annals of Hematology 4/2005

01.04.2005 | Original Article

Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information

verfasst von: Ulrike Bacher, Torsten Haferlach, Wolfgang Kern, Wolfgang Hiddemann, Susanne Schnittger, Claudia Schoch

Erschienen in: Annals of Hematology | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

In chronic myeloproliferative disorders other than CML (CMPD) recurrent cytogenetic abnormalities occur, but specific patterns of chromosomal aberrations in the specific entities have so far not been detected. Thus, the value of conventional cytogenetics in the routine diagnostic setting of CMPD remains to be clarified. We performed a cytogenetic study on 409 patients with different CMPD [polycythemia vera, essential thrombocytosis (ET), idiopathic osteomyelofibrosis, chronic myelomonocytic leukemia (proliferative subtype), idiopathic hypereosinophilic syndrome (HES), myeloproliferative syndrome (unclassifiable)] and on 102 patients with suspected CMPD. Cytogenetic abnormalities occurred in different frequencies ranging from 3 to 40% depending on the subtype, and showed some specific differences with respect to their type. The highest frequency and the most complex pattern of clonal aberrations were observed in idiopathic osteomyelofibrosis. However, clonal aberrations were also found in 10% of patients with suspected CMPD establishing the diagnosis of a malignant disease. In conclusion, cytogenetics are essential in the routine diagnostic setting of CMPD or cases suspicious for CMPD. In ET and in HES the aberration rate was only 3 and 7%, respectively. Thus, cytogenetics can be omitted. However, in some of these cases molecular procedures should be integrated into the routine diagnostic process.
Literatur
1.
Zurück zum Zitat Adewale A, Gordon D (2003) Cytogenetics of chronic myeloproliferative disorders and related myelodysplastic syndromes. Hematol Oncol Clin North Am 17:1129–1149 Adewale A, Gordon D (2003) Cytogenetics of chronic myeloproliferative disorders and related myelodysplastic syndromes. Hematol Oncol Clin North Am 17:1129–1149
2.
Zurück zum Zitat Bench AJ, Cross NCP, Huntly BJP, Nacheva EP, Green AR (2001) Myeloproliferative disorders. Best Pract 14:531–551CrossRef Bench AJ, Cross NCP, Huntly BJP, Nacheva EP, Green AR (2001) Myeloproliferative disorders. Best Pract 14:531–551CrossRef
3.
Zurück zum Zitat Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NCP, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201–1214CrossRefPubMed Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NCP, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201–1214CrossRefPubMed
4.
Zurück zum Zitat Coutre S, Gotlib J (2004) Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Semin Cancer Biol 14:23–31CrossRefPubMed Coutre S, Gotlib J (2004) Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Semin Cancer Biol 14:23–31CrossRefPubMed
5.
Zurück zum Zitat Cross NCP, Reiter A (2002) Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 16:1207–1212CrossRefPubMed Cross NCP, Reiter A (2002) Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 16:1207–1212CrossRefPubMed
6.
Zurück zum Zitat Goldman JM, Melo JV (2003) Mechanisms of disease—chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med 349:1451–1464CrossRefPubMed Goldman JM, Melo JV (2003) Mechanisms of disease—chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med 349:1451–1464CrossRefPubMed
7.
Zurück zum Zitat Groupe Français de Cytogénétique Hématologique (1986) Cytogenetics of chronic myelomonocytic leukemia. Cancer Genet Cytogenet 21:11–30 Groupe Français de Cytogénétique Hématologique (1986) Cytogenetics of chronic myelomonocytic leukemia. Cancer Genet Cytogenet 21:11–30
8.
Zurück zum Zitat Herishanu Y, Lishner M, Bomstein Y, Kitay-Cohen Y, Fejgin MD, Gaber E, Amiel A (2001) Comparative genomic hybridization in polycythemia vera and essential thrombocytosis patients. Cancer Genet Cytogenet 128:154–157CrossRefPubMed Herishanu Y, Lishner M, Bomstein Y, Kitay-Cohen Y, Fejgin MD, Gaber E, Amiel A (2001) Comparative genomic hybridization in polycythemia vera and essential thrombocytosis patients. Cancer Genet Cytogenet 128:154–157CrossRefPubMed
9.
Zurück zum Zitat Jaffe E, Lee Harris, Stein H, Vardiman JW (2001) Tumours of haematopoietic and lymphoid tissues. IARC, Lyon Jaffe E, Lee Harris, Stein H, Vardiman JW (2001) Tumours of haematopoietic and lymphoid tissues. IARC, Lyon
10.
Zurück zum Zitat Johansson B, Fioretos T, Mitelman F (2002) Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107:76–94CrossRefPubMed Johansson B, Fioretos T, Mitelman F (2002) Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107:76–94CrossRefPubMed
11.
Zurück zum Zitat Klippel S, Strunck E, Temerinac S, Bench AJ, Meinhardt G, Mohr U, Leichtle R, Green AR, Griesshammer M, Heimpel H, Pahl HL (2003) Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 102:3569–3574CrossRefPubMed Klippel S, Strunck E, Temerinac S, Bench AJ, Meinhardt G, Mohr U, Leichtle R, Green AR, Griesshammer M, Heimpel H, Pahl HL (2003) Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 102:3569–3574CrossRefPubMed
12.
Zurück zum Zitat Mertens F, Johansson B, Heim S, Kristoffersson U, Mitelman F (1991) Karyotypic patterns in chronic myeloproliferative disorders—report on 74 cases and review of the literature. Leukemia 5:214–220PubMed Mertens F, Johansson B, Heim S, Kristoffersson U, Mitelman F (1991) Karyotypic patterns in chronic myeloproliferative disorders—report on 74 cases and review of the literature. Leukemia 5:214–220PubMed
13.
Zurück zum Zitat Mitelman F (1995) An International System for Human Cytogenetic Nomenclature (1995): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature, Memphis, Tennessee, October 1994 Mitelman F (1995) An International System for Human Cytogenetic Nomenclature (1995): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature, Memphis, Tennessee, October 1994
14.
15.
Zurück zum Zitat Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R, Hiddemann W, Hochaus A (2003) Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 17:461–463CrossRefPubMed Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R, Hiddemann W, Hochaus A (2003) Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 17:461–463CrossRefPubMed
16.
Zurück zum Zitat Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T (2002) Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 16:53–59CrossRefPubMed Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T (2002) Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 16:53–59CrossRefPubMed
17.
Zurück zum Zitat Sessarego M, Defferrari R, Dejana AM, Rebuttato AM, Fugazza G, Salvidio E, Ajmar F (1989) Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation—a 12-year study. Cancer Genet Cytogenet 43:57–65CrossRefPubMed Sessarego M, Defferrari R, Dejana AM, Rebuttato AM, Fugazza G, Salvidio E, Ajmar F (1989) Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation—a 12-year study. Cancer Genet Cytogenet 43:57–65CrossRefPubMed
18.
Zurück zum Zitat Tefferi A (2000) Medical progress: myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255–1265CrossRefPubMed Tefferi A (2000) Medical progress: myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255–1265CrossRefPubMed
19.
Zurück zum Zitat Tefferi A, Lasho TL, Wolanskyj AP, Mesa RA (2004) Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood 103:3547–3548CrossRefPubMed Tefferi A, Lasho TL, Wolanskyj AP, Mesa RA (2004) Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood 103:3547–3548CrossRefPubMed
20.
Zurück zum Zitat Tefferi A, Meyer RG, Wyatt WA, Dewald GW (2001) Comparison of peripheral blood interphase cytogenetics with bone marrow karyotype analysis in myelofibrosis with myeloid metaplasia. Br J Haematol 115:316–319CrossRefPubMed Tefferi A, Meyer RG, Wyatt WA, Dewald GW (2001) Comparison of peripheral blood interphase cytogenetics with bone marrow karyotype analysis in myelofibrosis with myeloid metaplasia. Br J Haematol 115:316–319CrossRefPubMed
21.
Zurück zum Zitat Thiele J, Kvasnicka HM (2003) Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 82:148–152PubMed Thiele J, Kvasnicka HM (2003) Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 82:148–152PubMed
Metadaten
Titel
Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information
verfasst von
Ulrike Bacher
Torsten Haferlach
Wolfgang Kern
Wolfgang Hiddemann
Susanne Schnittger
Claudia Schoch
Publikationsdatum
01.04.2005
Erschienen in
Annals of Hematology / Ausgabe 4/2005
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-004-0977-1

Weitere Artikel der Ausgabe 4/2005

Annals of Hematology 4/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.